Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD (NCT04781140)
A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 Years Old) With Attention-Deficit/Hyperactivity Disorder (ADHD)
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
Who can join: Review the eligibility criteria below.
Location: The Center for Clinical Trials, Inc. — Saraland, Alabama
Age range: 48 Months to 69 Months
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (47 Sites)
Showing the first 25 of 47 sites.
- The Center for Clinical Trials, Inc. — Saraland, Alabama
- Preferred Research Partners, Inc. — Little Rock, Arkansas
- Advanced Research Center (ARC), Inc. — Anaheim, California
- Sun Valley Research Center — Imperial, California
- Alliance Research — Long Beach, California
- IMMUNOe Research Centers — Centennial, Colorado
- Luna Research Center — Coral Gables, Florida
- Sarkis Clinical Trials — Gainesville, Florida
- Clinical Neuroscience Solutions, Inc. — Jacksonville, Florida
- Avantis Clinical Research LLC — Miami, Florida
- Hope Research Network, LLC. — Miami, Florida
- Medical Research Group of Central Florida — Orange City, Florida
- Clinical Neuroscience Solutions, Inc. — Orlando, Florida
- APG Research LLC — Orlando, Florida
- D&H Tamarac Research Center — Tamarac, Florida
- Pediatric Neurology and Epilepsy Specialists — Winter Park, Florida
- Advanced Discovery Research LLC — Atlanta, Georgia
- Clinical Integrative Research Center of Atlanta — Atlanta, Georgia
- CenExcel iResearch, LLC — Decatur, Georgia
- CenExel iResearch, LLC. — Savannah, Georgia
- Qualmedica Research, LLC. — Evansville, Indiana
- Kentucky Pediatric/Adult Research — Bardstown, Kentucky
- Qualmedica Research, LLC. — Owensboro, Kentucky
- DelRicht Research (Touro Medical Center) — New Orleans, Louisiana
- DelRicht Research — Prairieville, Louisiana
📞 Contact the Study Coordinator
Phone: (240) 403-5324
Email: jhull@supernus.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Attention-Deficit/Hyperactivity Disorder
- Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) — Little Rock, Arkansas
- An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening — New York, New York
- A Pilot Study of a Remote ADHD Monitoring Program — Jackson, Mississippi
- The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder — Fayetteville, Arkansas
Explore by condition: All Attention-Deficit/Hyperactivity Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.